0000950170-24-001971.txt : 20240104
0000950170-24-001971.hdr.sgml : 20240104
20240104164038
ACCESSION NUMBER: 0000950170-24-001971
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240102
FILED AS OF DATE: 20240104
DATE AS OF CHANGE: 20240104
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Tregoning Kathleen
CENTRAL INDEX KEY: 0001830764
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38266
FILM NUMBER: 24512687
MAIL ADDRESS:
STREET 1: C/O CEREVEL THERAPEUTICS HOLDINGS, INC.
STREET 2: 131 DARTMOUTH STREET SUITE 502
CITY: BOSTON
STATE: MA
ZIP: 02116
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Spero Therapeutics, Inc.
CENTRAL INDEX KEY: 0001701108
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 675 MASSACHUSETTS AVENUE
STREET 2: 14TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 857-242-1600
MAIL ADDRESS:
STREET 1: 675 MASSACHUSETTS AVENUE
STREET 2: 14TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: Spero Therapeutics, LLC
DATE OF NAME CHANGE: 20170316
4
1
ownership.xml
4
X0508
4
2024-01-02
0001701108
Spero Therapeutics, Inc.
SPRO
0001830764
Tregoning Kathleen
C/O SPERO THERAPEUTICS, INC.
675 MASSACHUSETTS AVENUE, 14TH FLOOR
CAMBRIDGE
MA
02139
true
false
false
false
false
Stock Option (Right to Buy)
1.52
2024-01-02
4
A
false
35604
1.12
A
2034-01-02
Common Stock
35604
35604
D
This stock option shall vest in four quarterly installments on the last day of each calendar quarter during the calendar year subject to the Reporting Person's continued service as a non-employee director.
This stock option was issued to the Reporting Person, who elected to take stock options in lieu of $40,000 in cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation policy.
/s/ Tamara Joseph, Attorney-in-Fact for Kathleen Tregoning
2024-01-04